New
exogenous probes are needed for both imaging diagnostics and
therapeutics. Here, we introduce a novel nanocomposite near-infrared
(NIR) fluorescent imaging probe and test its potency as a photosensitizing
agent for photodynamic therapy (PDT) against triple-negative breast
cancer cells. The active component in the nanocomposite is a small
molecule, pyropheophorbide a-phosphatidylethanolamine-QSY21
(Pyro-PtdEtn-QSY), which is imbedded into lipid nanoparticles for
transport in the body. The probe targets abnormal choline metabolism
in cancer cells; specifically, the overexpression of phosphatidylcholine-specific
phospholipase C (PC–PLC) in breast, prostate, and ovarian cancers.
Pyro-PtdEtn-QSY consists of a NIR fluorophore and a quencher, attached
to a PtdEtn moiety. It is selectively activated by PC–PLC resulting
in enhanced fluorescence in cancer cells compared to normal cells.
In our in vitro investigation, four breast cancer
cell lines showed higher probe activation levels than noncancerous
control cells, immortalized human mammary gland cells, and normal
human T cells. Moreover, the ability of this nanocomposite to function
as a sensitizer in PDT experiments on MDA-MB-231 cells suggests that
the probe is promising as a theranostic agent.